<?xml version="1.0" encoding="UTF-8"?>
<p class="p">AD is a prevalent disease that affects more than 26 million people globally, and is the most common neurodegenerative disease worldwide [
 <xref rid="B7-pharmaceuticals-10-00084" ref-type="bibr" class="xref">7</xref>]. AChE inhibitors (AChEIs) have medical applications and are particularly important for the symptomatic treatment of Alzheimerâ€™s disease [
 <xref rid="B8-pharmaceuticals-10-00084" ref-type="bibr" class="xref">8</xref>]. The butyrylcholinesterase enzyme (BChE) is synthesized in the liver and its main function is to hydrolyze hydrophobic and hydrophilic carboxylic or phosphoric acid ester containing compounds. Its toxicological and pharmacological importance becomes clear when an individual is exposured to poisonous compounds targeting the acetylcholine binding sites. When there is a hepatic alteration, its concentration decreases in direct relation with the altered hepatocytes [
 <xref rid="B9-pharmaceuticals-10-00084" ref-type="bibr" class="xref">9</xref>,
 <xref rid="B10-pharmaceuticals-10-00084" ref-type="bibr" class="xref">10</xref>].
</p>
